Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 13/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.79 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304593 | 0.90 | MIF (0.81) | MIFHDAC6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL668287 | 0.88 | MIF (1.00) | MIFHDAC6 | |
| SCHEMBL667518 | 0.88 | MIF (1.00) | MIFHDAC6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL667764 | 0.88 | MIF (1.00) | MIFHDAC6 | |
| SCHEMBL455228 | 0.88 | MIF (1.00) | MIFHDAC6 | |
| SCHEMBL15082890 | 0.87 | MIF (0.79) | MIFHDAC6NPC1RAB9A | |
| SCHEMBL14642447 | 0.86 | MIF (0.78) | MIFHDAC6 | |
| SCHEMBL12517503 | 0.85 | MIF (0.75) | MIFHDAC6 | |
| SCHEMBL7372374 | 0.83 | MIF (0.72) | MIFHDAC6 | |
| SCHEMBL7373045 | 0.83 | MIF (0.72) | MIFHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552040-B2 | Isoxazoline compounds having MIF antagonist activity | CPSI STOCKHOLDER TRUST (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552040-B2 | Isoxazoline compounds having MIF antagonist activity | CPSI STOCKHOLDER TRUST (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1411930-B1 | ISOXAZOLINE COMPOUNDS HAVING MIF ANTAGONIST ACTIVITY | CYTOKINE PHARMASCIENCES INC (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-1411930-B1 | ISOXAZOLINE COMPOUNDS HAVING MIF ANTAGONIST ACTIVITY | CYTOKINE PHARMASCIENCES INC (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120046325-A1 | Isoxazoline Compounds Having MIF Antagonist Activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046325-A1 | Isoxazoline Compounds Having MIF Antagonist Activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7928130-B2 | Isoxazoline compounds having MIF antagonist activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928130-B2 | Isoxazoline compounds having MIF antagonist activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7662843-B2 | Isoxazoline compounds having MIF antagonist activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662843-B2 | Isoxazoline compounds having MIF antagonist activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100016391-A1 | Isoxazoline Compounds Having MIF Antagonist Activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016391-A1 | Isoxazoline Compounds Having MIF Antagonist Activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7491740-B2 | Isoxazoline compounds having MIF antagonist activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491740-B2 | Isoxazoline compounds having MIF antagonist activity | CYTOKINE PHARMASCIENCES, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040204464-A1 | Isoxazoline compounds having MIF antagonist activity | CPSI STOCKHOLDER TRUST | 2004-10-14 | — | — | US | disclosed |
| US-20030008908-A1 | Isoxazoline compounds having MIF antagonist activity | CPSI STOCKHOLDER TRUST | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008908-A1 | Isoxazoline compounds having MIF antagonist activity | MIF, PGF, HLA-DRB1 | MIF 1/4885HDAC6 1626/4885NPC1 4851/4885 |
| US-20120046325-A1 | Isoxazoline Compounds Having MIF Antagonist Activity | MIF, PGF, HMGB2 | MIF 1/4885HDAC6 1645/4885NPC1 4857/4885 |
| US-20040204464-A1 | Isoxazoline compounds having MIF antagonist activity | MIF, PGF, HLA-DRB1 | MIF 1/4885HDAC6 1626/4885NPC1 4851/4885 |
| US-20100016391-A1 | Isoxazoline Compounds Having MIF Antagonist Activity | MIF, PGF, HMGB2 | MIF 1/4885HDAC6 1645/4885NPC1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.